Jarom Heijmans

Dr. Jarom Heijmans

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2020 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
SMSaskia Middeldorp
Saskia Middeldorp
MCMichiel Coppens
Michiel Coppens
THThijs F. van Haaps
Thijs F. van Haaps
MFMerijn Foppen
Merijn Foppen
AVAlexander P. J. Vlaar
Alexander P. J. Vlaar
NENick van Es
Nick van Es
Coronavirus disease 2019 (COVID‐19) can lead to systemic coagulation activation and thrombotic complications. We investigated the incidence of objectively confirmed venous thromboembolism (VTE) in 198 hospitalized patients with COVID‐19 in a single‐center cohort study. Seventy‐five patients (38%) were admitted to the intensive care unit (ICU). At time of data collection, 16 (8%) were still hospitalized and 19% had died. During a median follow‐up of 7 days (IQR, 3‐13), 39 patients (20%) were diagnosed with VTE of whom 25 (13%) had symptomatic VTE, despite routine thrombosis prophylaxis. The cumulative incidences of VTE at 7, 14 and 21 days were 16% (95% CI, 10‐22), 33% (95% CI, 23‐43) and 42% (95% CI 30‐54) respectively. For symptomatic VTE, these were 10% (95% CI, 5.8‐16), 21% (95% CI, 14‐30) and 25% (95% CI 16‐36). VTE appeared to be associated with death (adjusted HR, 2.4; 95% CI, 1.02‐5.5). The cumulative incidence of VTE was higher in the ICU (26% (95% CI, 17‐37), 47% (95% CI, 34‐58), and 59% (95% CI, 42‐72) at 7, 14 and 21 days) than on the wards (any VTE and symptomatic VTE 5.8% (95% CI, 1.4‐15), 9.2% (95% CI, 2.6‐21), and 9.2% (2.6‐21) at 7, 14, and 21 days). The observed risk for VTE in COVID‐19 is high, particularly in ICU patients, which should lead to a high level of clinical suspicion and low threshold for diagnostic imaging for DVT or PE. Future research should focus on optimal diagnostic and prophylactic strategies to prevent VTE and potentially improve survival.

21 June 2019 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
CSClaudia N. Spaan
Claudia N. Spaan
WSWouter L. Smit
Wouter L. Smit
JJJooske F. van Lidth de Jeude
Jooske F. van Lidth de Jeude
BMBartolomeus J. Meijer
Bartolomeus J. Meijer
VMVanesa Muncan
Vanesa Muncan
JHJarom Heijmans
Jarom Heijmans
The unfolded protein response (UPR) acts through its downstream branches, PERK-eIF2α signaling, IRE1α-XBP1 signaling and ATF6 signaling. In the intestine, activation of the UPR through the kinase PERK results in differentiation of intestinal epithelial stem cells and colon cancer stem cells, whereas deletion of XBP1 results in increased stemness and adenomagenesis. How downstream activation of XBP1 and ATF6 influences intestinal stemness and proliferation remains largely unknown. We generated colorectal cancer cells (LS174T) that harbor doxycycline inducible expression of the active forms of either XBP1(s) or ATF61-373. Activation of either XBP1 or ATF6 resulted in reduced cellular proliferation and reduced expression of markers of intestinal epithelial stemness. Moreover, XBP1 and ATF6 activation reduced global protein synthesis and lowered the threshold for UPR activation. XBP1-mediated loss of stemness and proliferation resulted from crossactivation of PERK-eIF2α signaling and could be rescued by constitutive expression of eIF2α phosphatase GADD34. We thus find that enforced activation of XBP1 and ATF6 results in reduction of stemness and proliferation. We expose a novel interaction between XBP1 and PERK-eIF2α signaling.

28 September 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
WSWouter Laurentius Smit
Wouter Laurentius Smit
CSClaudia Nanette Spaan
Claudia Nanette Spaan
RBRuben Johannes de Boer
Ruben Johannes de Boer
PRPrashanthi Ramesh
Prashanthi Ramesh
TGTânia Martins Garcia
Tânia Martins Garcia
JHJarom Heijmans
Jarom Heijmans
Significance: Deregulated global mRNA translation is a feature of various cancers and considered important in oncogenic transformation. In colorectal cancer (CRC), the role of the most common driver mutations in APC , KRAS , SMAD4 , and TP53 on the global translational capacity are incompletely understood. Here, using mouse and human intestinal organoids, we found that each mutation governs the global translational capacity of the epithelial cell. Global translation is linked to known oncogenic hallmarks, including cell proliferation and growth upon accumulation of these mutations, posing the translational apparatus as a potential therapeutic target in CRC.

1 March 2019 in Science
Verified
Journal Article
Closed access
PDF file
JGJoep Grootjans
Joep Grootjans
NKNiklas Krupka
Niklas Krupka
SHShuhei Hosomi
Shuhei Hosomi
JMJuan D. Matute
Juan D. Matute
THThomas Hanley
Thomas Hanley
RBRichard S. Blumberg
Richard S. Blumberg
Stressed gut epithelium gets some relief: Immunoglobulin A (IgA) is the most abundantly expressed antibody isotype and can be found at various mucosal surfaces in the body, including the gastrointestinal (GI) tract. IgA is polyreactive and can coat and restrain both commensal bacteria and enteric pathogens. Grootjans et al. found that endoplasmic reticulum (ER) stress in the intestinal epithelial cells of mice induced the T cell– and microbiota-independent expansion of peritoneal B1b cells, which secrete IgA. Similarly, human subjects homozygous for a variant of an autophagy gene ( ATG16L1 ) known to cause ER stress showed increased numbers of GI IgA + cells compared with controls. Thus, epithelial ER stress serves as an advantageous “eustress” response that can functionally antagonize its well-characterized role in promoting inflammation. Science , this issue p. 993

4 August 2022 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
SHSammy Huygens
Sammy Huygens
QHQuincy Hofsink
Quincy Hofsink
INInger S Nijhof
Inger S Nijhof
AGAbraham Goorhuis
Abraham Goorhuis
AKArnon P Kater
Arnon P Kater
JHJarom Heijmans
Jarom Heijmans
The aim of this randomized, controlled trial is to determine whether antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against severe coronavirus disease 2019 (COVID-19) in severely immunocompromised, hospitalized, COVID-19 patients. Patients were randomly assigned to receive COVIG or intravenous immunoglobulin (IVIG) without SARS-CoV-2 antibodies. Severe COVID-19 was observed in 2 of 10 (20%) patients treated with COVIG compared to 7 of 8 (88%) in the IVIG control group (P = .015, Fisher’s exact test). Antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin may be a valuable treatment in severely immunocompromised, hospitalized, COVID-19 patients and should be considered when no monoclonal antibody therapies are available.

18 June 2020 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
MKMaria T. Kuipers
Maria T. Kuipers
RZRob van Zwieten
Rob van Zwieten
JHJarom Heijmans
Jarom Heijmans
CRCaroline E. Rutten
Caroline E. Rutten
KHKoen de Heer
Koen de Heer
ENErfan Nur
Erfan Nur
Click on the article title to read more.